Assessing cardiac insufficiency risks of aflatoxin B1 through network toxicology and molecular docking analyses

Qianyao Zhang1, Qing Zhang2, Piqiao Jiang3

  • 1Department of cardiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110000, China.

PubMed

Insights

Aflatoxin B1 (AFB1) promotes cardiac insufficiency by activating JAK2, PI3K-AKT, and MAPK pathways. This study reveals the molecular mechanisms behind AFB1-induced heart problems, offering insights for potential interventions.

Area of Science:

  • Toxicology
  • Cardiovascular Biology
  • Molecular Biology

Background:

  • Aflatoxin B1 (AFB1) is a mycotoxin known for its toxicity.
  • Cardiac insufficiency is a significant health concern with complex underlying mechanisms.

Purpose of the Study:

  • To elucidate the promoting effect of Aflatoxin B1 (AFB1) on cardiac insufficiency.
  • To identify the specific molecular mechanisms involved in AFB1-induced cardiac dysfunction.

Main Methods:

  • Network toxicology, molecular docking, and dynamics simulations were employed.
  • Protein-protein interaction (PPI) network analysis identified 12 core genes.
  • In vivo murine experiments validated the molecular findings.

Main Results:

  • 44 overlapping targets between cardiac insufficiency and AFB1 toxicity were identified.
  • AFB1 strongly binds to core targets, particularly JAK2, GSK3B, and MMP9.
  • AFB1 exposure activates PI3K-AKT and MAPK signaling pathways, leading to cardiac insufficiency.

Conclusions:

  • AFB1 binding to JAK2 initiates the activation of PI3K-AKT and MAPK pathways.
  • This activation promotes cardiac insufficiency, establishing a molecular link between AFB1 exposure and heart dysfunction.
  • The study provides a theoretical framework for understanding AFB1's role in exacerbating cardiac insufficiency.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
185
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.9K
Toxic Reactions: Overview01:26

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
1.8K